Home » Open Orphan (ORPH) » Built to sell – can dealmaker Cathal Friel build (and sell) a £80m company in two years?

Built to sell – can dealmaker Cathal Friel build (and sell) a £80m company in two years?

by Sean Keyes | Financial Correspondant

Serial dealmaker Cathal Friel has an audacious plan: build and sell a pharma services company in two years. It could fetch as much as £100 million. What exactly is his plan? And will it work?

On the cover of the fifth edition of Dr John Oxford’s book Human Virology is a picture of the Wuhan strain of the coronavirus. It was published in 2016.

The virus spherical, with hundreds of nasty looking bulbous projections on its surface. Viewed through a microscope, the projections resemble the sun’s corona. Hence the name.

Showing me Dr Oxford’s book is Cathal Friel, the Chairman of the small cap pharma services company Open Orphan (LN:ORPH). Friel is showing me the book because five weeks ago his company, Open Orphan, acquired the virus-fighting company founded by Dr Oxford.

The company is called hViVo….

Link here to login and read full article


Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.